The European Commission today published the evaluation of the Antimicrobial Resistance (AMR) Action Plan (2011-2016).
The evaluation concludes that the Action Plan had a clear European Union added value acting as a symbol of political commitment, stimulating several actions within member states, and has served to strengthen international cooperation.
The Action Plan has also provided a framework to guide and coordinate activities on AMR at the international level in the area of monitoring and surveillance and on R&D. The evaluation shows that there is a clear need to support and assist member states in developing and implementing national action plans to reduce differences between them in the use of antimicrobials and prevalence of infections, to foster collaboration across sectors, to improve knowledge of citizens and to strengthen monitoring and surveillance systems by developing expertise on methodologies, solid indicators and instruments.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze